On July 9, 2025, Lixte Biotechnology Holdings, Inc. announced via press release that the Medical Journal 'Nature' has validated the scientific basis for its clinical trials on Ovarian and Colorectal cancers. This endorsement supports the company's ongoing research efforts in these critical areas.